Is Tarsus Pharmaceuticals Inc (TARS) overvalued? · rev $183.0M
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
This page asks whether Tarsus Pharmaceuticals Inc (TARS) looks expensive on cached numbers — not a short thesis.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
TARS currently screens at market cap $2.66B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TARS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TARS stock page for the full model, not this heading.
Not investment advice.